Who is Zydus

Company Milestones

Zydus currently offers over 80 FDA-approved generic products across a wide variety of therapeutic categories in the US. To learn more about our history, select one of the time frames below.

The Beginnings 2001 - 2006 2007 - 2012 2013 - 2018
Pre 2000

1952 – Cadila Laboratories Ltd. established by Mr. Ramanbhai B. Patel

Pre 2000

1950s – 1960s – Cadila made a mark with innovative medicines such as Livirubra, the first of its kind in India to treat pernicious anemia

Pre 2000

1970s – 1980s – Cadila became a benchmark for Quality and Excellence

Pre 2000

1995-1996 – Zydus’s journey began with Rs 250 crs.

Pre 2000

1995-1996 – Acquired Indo Pharma Pharmaceutical Works Ltd – the group’s first acquisition

Pre 2000

1995-1996 – Launched 23 new products in 1995, with first-in-India like Falcigo

Pre 2000

1997-1998 – Entered into JV with BYK Gulden, a German pharma major to set up a 50:50 JV

Pre 2000

1999-2000 – Entered into capital markets through Initial Public Offering (IPO)

Pre 2000

1999-2000 – Entered into JV with Sarabhai for consolidating its position in Animal Healthcare

Pre 2000

2000-2001 – Acquired Recon Healthcare, which boosted Zydus’s strengths in southern markets

Pre 2000

2000-2001 – Zydus Research Centre set up at Moraiya

Pre 2000

2000-2002 – Acquired German Remedies – the largest M&A in the Indian pharmaceutical sector at the time

01-06

2001-2002 – Acquired Aten and attained the top spot in the cardiovascular segment in India

01-06

2001-2002 – Acquired USFDA approved API plant,
Banyan Chemicals

01-06

2002-2003 – Zydus Pharmaceuticals (USA) Inc. incorporated

01-06

2003-2004 – Acquired Alpharma France (renamed Zydus France) – Zydus’s first international acquisition

01-06

2004-2005 – Filed first IND in India for ZYH11

01-06

2005-2006 – Acquired 30.7% stake in Carnation Nutra Analogue Foods Ltd

01-06

2006-2007 – Acquired Liva Healthcare and entered the dermatology market in India

01-06

2006-2007 – Acquired Nippon Universal and entered the Japanese market

07-12

2007-2008 – Entered into branded generic market of Brazil with the acquisition of Quimica e Farmaceutica Nikkho do Brasil Ltda

07-12

2008-2009 – Acquired Laboratorios Combix in Spain, Simayla Pharma in South America, and Etna Biotech in Italy

07-12

2009-2010 – Launched first formulation using nano-technology platform in India – Oxalgin Nanogel

07-12

2010-2011 – Achieved $1 billion in sales

07-12

2010-2011 – Entered into a 50:50 JV with Bayer to set up a new marketing company

07-12

2010-2011 – Launched Vaxiflu – S, India’s first H1N1 vaccine

07-12

2010-2011 – Entered into strategic agreement with Abbott for commercializing branded generics in emerging markets

07-12

2011-2012 – Acquired the assets of US-based Nesher Pharmaceuticals Inc.

07-12

2011-2012 – Received USFDA approval of Baddi manufacturing plant

07-12

2011-2012 – Acquired 100% stake in Biochem, one of the top 40 pharma companies in India

07-12

2011-2012 – Acquired Bremer Pharma GmbH to gain a global footprint in the animal healthcare business

07-12

2012-2013 – Over 114 new products launched during the year, 31 of which were first in India launches

13-18

2013 – Received USFDA approval for initiating Phase I clinical trials of ZYDPLA1, a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes

13-18

2014 – Zydus launched world’s first biosimilar of adalimumab

13-18

2015 – Zydus began Phase III study of saroglitazar in NASH

13-18

2016 – Zydus acquired Zoetis, a global animal health company

13-18

2016 – Zydus began supplying product in the US market from its SEZ facility

13-18

2016 – Zydus’s Nesher Pharmaceuticals received its first ANDA approval, dextroamphetamine tablets

13-18

2016 – Zydus received approval from the USFDA to initiate Phase II clinical trials of saroglitazar in patients with Non-Alcoholic Steatohepatitis (NASH) of the liver in the US

13-18

2016 – Zydus and Takeda entered into partnership to address emerging infection diseases

13-18

2017 – Zydus Cadila acquired Sentynl Therapeutics Inc., US-based specialty company

13-18

2017 – Zydus launched India’s first Tetravalent Inactivated Influenza vaccine – VaxiFlu – 4

13-18

2017 – Zydus received USFDA approval to initiate Phase II clinical studies of saroglitazar in patients with Primary Biliary Cholangitis (PBC)

13-18

2017 – Zydus started Phase II trial of ZYAN1 for treating anemia in patients with CKD

13-18

2017 – Zydus received regulatory approval of LipaglynTM in Mexico

13-18

2018 – Cadila Healthcare acquired 51% stake in Windlas Healthcare

13-18

2018 – Zydus partnered with Medicure to launch its NDA product, ZYPITAMAG